KalVista Pharmaceuticals, Inc. (KALV)

Market Cap	254.56M
Revenue (ttm)	n/a
Net Income (ttm)	-90.72M
Shares Out	34.17M
EPS (ttm)	-3.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	409,110
Open	6.83
Previous Close	6.81
Day's Range	6.83 - 7.46
52-Week Range	4.12 - 17.06
Beta	1.11
Analysts	Buy
Price Target	19.72 (+164.7%)
Earnings Date	Mar 9, 2023

About KALV

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Mr. Thomas Andrew Crockett M.B.A.
• Employees: 105
• Stock Exchange: NASDAQ
• Ticker Symbol: KALV

Analyst Forecast

According to 12 analysts, the average rating for KALV stock is "Buy." The 12-month stock price forecast is $19.72, which is an increase of 164.70% from the latest price.

Price Target

$19.72

(164.70% upside)

Analyst Consensus: Buy